Targeted and immunotherapeutic approaches in brain metastases.
Targeted and immunotherapeutic approaches in brain metastases.
复制标题
DOI：
10.14694/edbook_am.2015.35.67
复制
发表时间：
2015-01-01
期刊：
影响因子：
--
通讯作者：
Winkler, Frank
中科院分区：
文献类型：
--
作者：
Ahluwalia, Manmeet S;Winkler, Frank
脑转移是癌症的常见和毁灭性的并发症。脑转移瘤的治疗方法通常是多学科的，包括手术、全脑放射治疗（WBRT）、立体定向放射外科（SRS）和全身治疗药物。直到最近，由于缺乏活性、血脑屏障穿透的挑战、异质性患者人群和大量预治疗患者人群，全身治疗在脑转移瘤的管理中的作用有限。对脑转移瘤生物学和分子定义的疾病亚群的理解的进展促进了新型治疗药物（包括靶向治疗和免疫治疗）在脑转移瘤管理中的新兴作用。
Brain metastases are a common and devastating complication of cancer. The approach to the management of brain metastases is often multidisciplinary and includes surgery, whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and systemic therapeutic agents. Until recently, systemic therapy has had a limited role in the management of brain metastases because of a lack of activity, challenges of blood-brain barrier penetration, the heterogeneous patient population, and a heavily pretreated patient population. Advances in the understanding of the biology of brain metastases and molecularly defined disease subsets have facilitated an emerging role of novel therapeutic agents, including targeted therapies and immunotherapy, in the management of brain metastases.